Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
386. |
ECCT/13/08/02 | MalPaC Trial Comparing drug-regimens for clearing parasites in Phase IIb trial designs prior to PCR monitoring for Plasmodium falciparum infection. |
Principal Investigator(s) 1. Caroline Amolo Ogwang 2. Francis Maina Ndung\'u Site(s) in Kenya Junju |
View |
387. |
ECCT/24/03/03 | DoxyDOT Study Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI CMR RCTP |
View |
388. |
ECCT/21/08/01 | CARES Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa. |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya 1. AMPATH Eldoret (Uasin Gishu county) 2. Aghakhan University (Nairobi City county) 3. Kericho KEMRI WRP CRC site (Kericho county) |
View |
389. |
ECCT/13/05/02 | An open-label randomized controlled trial of the efficacy and safety of Clindamycin plus quinine compared with artemether-lumefantrine for the treatment of children with uncomplicated falciparum malaria in western Kenya |
Principal Investigator(s) 1. CHARLES OWUORA OBONYO Site(s) in Kenya Ahero Sub-district Hospital |
View |
390. |
ECCT/22/08/04 | Protocol H06_01TP A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2) |
Principal Investigator(s) 1. Deborah Chepngeno Langat Langat Site(s) in Kenya KEMRI WRP CRC KERICHO |
View |